Related Experiment Video
Updated: Jul 14, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
The pharmacogenetics of methotrexate
S L Hider1, I N Bruce, W Thomson
1Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT UK.
Rheumatology (Oxford, England)
|June 26, 2007
Summary
Predicting rheumatoid arthritis treatment response to methotrexate (MTX) is challenging. Pharmacogenetics, studying genetic influences on drug response, offers potential insights into MTX efficacy and adverse events, but requires further research.
Area of Science:
- Rheumatology
- Pharmacology
- Genetics
Background:
- Methotrexate (MTX) is a primary treatment for rheumatoid arthritis.
- A significant portion of patients (up to one-third) do not respond effectively to MTX due to inefficacy or adverse events.
- Current methods cannot accurately predict individual patient responses to MTX therapy.
Purpose of the Study:
- To critically review existing studies on the pharmacogenetics of methotrexate.
- To identify the role of genetic variations in predicting MTX response in rheumatoid arthritis.
- To highlight areas for future research in MTX pharmacogenetics.
Main Methods:
- Literature review of pharmacogenetic studies related to methotrexate.
- Analysis of key enzymes involved in MTX intracellular metabolism.
- Critical appraisal of studies investigating genetic factors influencing MTX efficacy and toxicity.
Main Results:
- Methotrexate has a complex metabolic pathway involving multiple enzymes.
- Genetic variations in these enzymes may influence MTX efficacy and adverse events.
- Existing pharmacogenetic data for MTX is fragmented and requires further investigation.
Conclusions:
- Pharmacogenetics holds promise for personalizing MTX therapy in rheumatoid arthritis.
- Further well-designed studies are needed to elucidate the genetic determinants of MTX response.
- Accurate prediction of MTX therapy response remains an unmet clinical need.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...